Promising Results for Depression Treatment with Microdosing LSD

MindBio Therapeutics Corp. (CSE) has recently unveiled promising durability data from its Phase 2A clinical trials, which tested MB22001, the company’s innovative self-administered, take-home microdose of Lysergic Acid Diethylamide (LSD), as a treatment for depression.

This development underscores MindBio’s commitment to advancing psychedelic medicine as a viable option for mental health treatment.

Read more

Resources for Post-Psychedelic Difficulties

Shared from Ecstatic Integration.

If you’re dealing with post-psychedelic difficulties, here are some resources:

Fireside Project​ is a phone support service for people experiencing psychedelic or post-psychedelic difficulties.

ICEERS is a plant medicine NGO which has a free support centre.

A university clinic in Berlin which provides free consultations on post-psychedelic difficulties

Cheetah House also offers consultations on post-psychedelic and post-meditation adverse experiences.

The Challenging Psychedelic Experiences Project offers a free online support group for post-psychedelic difficulties on the last Sunday of every month (next one August 25th). We also have research on post-psychedelic difficulties and what helps people cope with them, including a new paper on post-psychedelic existential confusion and ontological shock.

Read more

Three Studies of MDMA Treatment Retracted by Scientific Journal

The journal Psychopharmacology has retracted three papers about MDMA-assisted therapy based on what the publication said was unethical conduct at one of the study sites where the research took place.

Several of the papers’ authors are affiliated with Lykos Therapeutics, the drug company whose application for MDMA-assisted therapy to treat post-traumatic stress disorder was rejected last week by the Food and Drug Administration.

Read more